Adrenocortical dysfunction in polycystic ovary syndrome

Bulent O. Yildiz, Ricardo Azziz

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Citations (Scopus)

Abstract

Introduction: Androgen excess is the most common endocrine disorder of reproductive-aged women, with the majority of patients having a functional abnormality, namely polycystic ovary syndrome (PCOS) (Azziz et al. 2004a). We and others have reported the estimated prevalence of this syndrome to be approximately 6–8% (Knochenhauer et al. 1998, Diamanti-Kandarakis et al. 1999, Asunción et al. 2000, Azziz et al. 2004b), using the 1990 National Institute of Child Health and Human Development (NICHD) conference diagnostic criteria for PCOS (Zawadzki and Dunaif 1992). This conference concluded that the diagnostic criteria of PCOS should include: (1) clinical and/or biochemical signs of hyperandrogenism, (2) oligo-ovulation, and (3) exclusion of other known disorders such as Cushing's syndrome, hyperprolactinemia, and non-classic congenital adrenal hyperplasia (NCAH) (Zawadzki and Dunaif 1992). A recent expert meeting sponsored by the European Society of Human Reproduction and Embryology (ESHRE) and the American Society for Reproductive Medicine (ASRM) expanded this definition, noting that PCOS should be diagnosed when at least two of the following three criteria are present: (1) oligo- and/or anovulation, (2) clinical and/or biochemical signs of hyperandrogenism, or (3) polycystic ovaries on ultrasonography, after the exclusion of related disorders (The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group 2004a, b). The adrenal androgens (AAs) are primarily secreted by the zonae reticulares of the adrenal cortex, and include dehydroepiandrosterone (DHEA) and its sulfate (DHEAS), Δ5-androstene-3β, 17β-diol (androstenediol), and 11β-hydroxyandrostenedione (11-OHA4).

Original languageEnglish (US)
Title of host publicationPolycystic Ovary Syndrome, Second Edition
PublisherCambridge University Press
Pages288-315
Number of pages28
ISBN (Electronic)9780511545191
ISBN (Print)0521848490, 9780521848497
DOIs
StatePublished - Jan 1 2007

Fingerprint

Polycystic Ovary Syndrome
Hyperandrogenism
Androgens
Androstenediol
Consensus Development Conferences
National Institute of Child Health and Human Development (U.S.)
Anovulation
Reproductive Medicine
Dehydroepiandrosterone Sulfate
Hyperprolactinemia
Embryology
Cushing Syndrome
Adrenal Cortex
Herpes Zoster
Ovulation
Reproduction
Ovary
Ultrasonography

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Yildiz, B. O., & Azziz, R. (2007). Adrenocortical dysfunction in polycystic ovary syndrome. In Polycystic Ovary Syndrome, Second Edition (pp. 288-315). Cambridge University Press. https://doi.org/10.1017/CBO9780511545191.017

Adrenocortical dysfunction in polycystic ovary syndrome. / Yildiz, Bulent O.; Azziz, Ricardo.

Polycystic Ovary Syndrome, Second Edition. Cambridge University Press, 2007. p. 288-315.

Research output: Chapter in Book/Report/Conference proceedingChapter

Yildiz, BO & Azziz, R 2007, Adrenocortical dysfunction in polycystic ovary syndrome. in Polycystic Ovary Syndrome, Second Edition. Cambridge University Press, pp. 288-315. https://doi.org/10.1017/CBO9780511545191.017
Yildiz BO, Azziz R. Adrenocortical dysfunction in polycystic ovary syndrome. In Polycystic Ovary Syndrome, Second Edition. Cambridge University Press. 2007. p. 288-315 https://doi.org/10.1017/CBO9780511545191.017
Yildiz, Bulent O. ; Azziz, Ricardo. / Adrenocortical dysfunction in polycystic ovary syndrome. Polycystic Ovary Syndrome, Second Edition. Cambridge University Press, 2007. pp. 288-315
@inbook{ffedd172f0dc41179a1d9f87a50e428e,
title = "Adrenocortical dysfunction in polycystic ovary syndrome",
abstract = "Introduction: Androgen excess is the most common endocrine disorder of reproductive-aged women, with the majority of patients having a functional abnormality, namely polycystic ovary syndrome (PCOS) (Azziz et al. 2004a). We and others have reported the estimated prevalence of this syndrome to be approximately 6–8{\%} (Knochenhauer et al. 1998, Diamanti-Kandarakis et al. 1999, Asunci{\'o}n et al. 2000, Azziz et al. 2004b), using the 1990 National Institute of Child Health and Human Development (NICHD) conference diagnostic criteria for PCOS (Zawadzki and Dunaif 1992). This conference concluded that the diagnostic criteria of PCOS should include: (1) clinical and/or biochemical signs of hyperandrogenism, (2) oligo-ovulation, and (3) exclusion of other known disorders such as Cushing's syndrome, hyperprolactinemia, and non-classic congenital adrenal hyperplasia (NCAH) (Zawadzki and Dunaif 1992). A recent expert meeting sponsored by the European Society of Human Reproduction and Embryology (ESHRE) and the American Society for Reproductive Medicine (ASRM) expanded this definition, noting that PCOS should be diagnosed when at least two of the following three criteria are present: (1) oligo- and/or anovulation, (2) clinical and/or biochemical signs of hyperandrogenism, or (3) polycystic ovaries on ultrasonography, after the exclusion of related disorders (The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group 2004a, b). The adrenal androgens (AAs) are primarily secreted by the zonae reticulares of the adrenal cortex, and include dehydroepiandrosterone (DHEA) and its sulfate (DHEAS), Δ5-androstene-3β, 17β-diol (androstenediol), and 11β-hydroxyandrostenedione (11-OHA4).",
author = "Yildiz, {Bulent O.} and Ricardo Azziz",
year = "2007",
month = "1",
day = "1",
doi = "10.1017/CBO9780511545191.017",
language = "English (US)",
isbn = "0521848490",
pages = "288--315",
booktitle = "Polycystic Ovary Syndrome, Second Edition",
publisher = "Cambridge University Press",

}

TY - CHAP

T1 - Adrenocortical dysfunction in polycystic ovary syndrome

AU - Yildiz, Bulent O.

AU - Azziz, Ricardo

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Introduction: Androgen excess is the most common endocrine disorder of reproductive-aged women, with the majority of patients having a functional abnormality, namely polycystic ovary syndrome (PCOS) (Azziz et al. 2004a). We and others have reported the estimated prevalence of this syndrome to be approximately 6–8% (Knochenhauer et al. 1998, Diamanti-Kandarakis et al. 1999, Asunción et al. 2000, Azziz et al. 2004b), using the 1990 National Institute of Child Health and Human Development (NICHD) conference diagnostic criteria for PCOS (Zawadzki and Dunaif 1992). This conference concluded that the diagnostic criteria of PCOS should include: (1) clinical and/or biochemical signs of hyperandrogenism, (2) oligo-ovulation, and (3) exclusion of other known disorders such as Cushing's syndrome, hyperprolactinemia, and non-classic congenital adrenal hyperplasia (NCAH) (Zawadzki and Dunaif 1992). A recent expert meeting sponsored by the European Society of Human Reproduction and Embryology (ESHRE) and the American Society for Reproductive Medicine (ASRM) expanded this definition, noting that PCOS should be diagnosed when at least two of the following three criteria are present: (1) oligo- and/or anovulation, (2) clinical and/or biochemical signs of hyperandrogenism, or (3) polycystic ovaries on ultrasonography, after the exclusion of related disorders (The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group 2004a, b). The adrenal androgens (AAs) are primarily secreted by the zonae reticulares of the adrenal cortex, and include dehydroepiandrosterone (DHEA) and its sulfate (DHEAS), Δ5-androstene-3β, 17β-diol (androstenediol), and 11β-hydroxyandrostenedione (11-OHA4).

AB - Introduction: Androgen excess is the most common endocrine disorder of reproductive-aged women, with the majority of patients having a functional abnormality, namely polycystic ovary syndrome (PCOS) (Azziz et al. 2004a). We and others have reported the estimated prevalence of this syndrome to be approximately 6–8% (Knochenhauer et al. 1998, Diamanti-Kandarakis et al. 1999, Asunción et al. 2000, Azziz et al. 2004b), using the 1990 National Institute of Child Health and Human Development (NICHD) conference diagnostic criteria for PCOS (Zawadzki and Dunaif 1992). This conference concluded that the diagnostic criteria of PCOS should include: (1) clinical and/or biochemical signs of hyperandrogenism, (2) oligo-ovulation, and (3) exclusion of other known disorders such as Cushing's syndrome, hyperprolactinemia, and non-classic congenital adrenal hyperplasia (NCAH) (Zawadzki and Dunaif 1992). A recent expert meeting sponsored by the European Society of Human Reproduction and Embryology (ESHRE) and the American Society for Reproductive Medicine (ASRM) expanded this definition, noting that PCOS should be diagnosed when at least two of the following three criteria are present: (1) oligo- and/or anovulation, (2) clinical and/or biochemical signs of hyperandrogenism, or (3) polycystic ovaries on ultrasonography, after the exclusion of related disorders (The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group 2004a, b). The adrenal androgens (AAs) are primarily secreted by the zonae reticulares of the adrenal cortex, and include dehydroepiandrosterone (DHEA) and its sulfate (DHEAS), Δ5-androstene-3β, 17β-diol (androstenediol), and 11β-hydroxyandrostenedione (11-OHA4).

UR - http://www.scopus.com/inward/record.url?scp=41749098498&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41749098498&partnerID=8YFLogxK

U2 - 10.1017/CBO9780511545191.017

DO - 10.1017/CBO9780511545191.017

M3 - Chapter

AN - SCOPUS:41749098498

SN - 0521848490

SN - 9780521848497

SP - 288

EP - 315

BT - Polycystic Ovary Syndrome, Second Edition

PB - Cambridge University Press

ER -